The global dasatinib market is gaining steady traction as demand rises for targeted therapies used in hematologic malignancies, especially chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). According to Grand View Research, the market was estimated at USD 5.59 billion in 2025 and is projected to reach USD 7.57 billion by 2033, expanding at a CAGR of 4.27% from 2026 to 2033.
Growth is being supported by stronger diagnosis rates, wider acceptance of tyrosine kinase inhibitors, and the continued shift toward precision oncology. The expanding use of generic formulations is also improving affordability and access across both mature and emerging healthcare markets.
Market Segmentation
By Drug Type: The generic segment led the market in 2025 with a 69.24% share, reflecting patent expirations, broader manufacturer participation, and improved accessibility for patients and providers. Branded dasatinib continues to retain relevance in certain treatment pathways, but generics are reshaping the competitive landscape through lower pricing and wider distribution.
By Indication: CML accounted for the largest share in 2025 at 59.93%, since dasatinib is widely used as a standard targeted therapy for Ph+ CML across chronic, accelerated, and blast phases. The ALL segment is also expanding, supported by increasing use in Ph+ ALL and ongoing clinical studies that are broadening its therapeutic profile.
By Distribution Channel: Hospital pharmacies dominated the market in 2025 with a 58.62% share, driven by oncology prescribing patterns, specialist supervision, and controlled dispensing practices. Retail, online, and specialty oncology pharmacies are also important, with online channels expected to gain traction as e-prescribing and remote access continue to expand.
By Region: North America remained the largest regional market in 2025 with a 54.17% share, supported by advanced oncology infrastructure, strong reimbursement systems, and high awareness of targeted therapies. Asia Pacific is expected to be the fastest-growing region, with Grand View Research reporting revenue of USD 791.9 million in 2025 and a projected USD 1,232.1 million by 2033 at a 5.6% CAGR.
Looking for more specific insights? Customize this report to suite your business needs
Competitive Landscape
The dasatinib market is becoming more competitive as generic manufacturers increase their presence and broaden patient access. Grand View Research highlights leading companies including Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Sun Pharmaceutical Industries Limited, Hetero Drugs Limited, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, and Lupin Limited.
Recent market developments show how active the generic opportunity has become. Grand View Research notes that Lupin Limited launched dasatinib tablets in the U.S. in February 2026, while Alembic Pharmaceuticals Limited received U.S. FDA approval in November 2025 and Aurobindo Pharma received approval in April 2025.
Company Profiles
Bristol-Myers Squibb Company remains the most prominent branded-name player in the dasatinib space, supported by its long-standing oncology portfolio and clinical legacy in leukemia treatment. Its market position is closely tied to the established brand and physician familiarity associated with dasatinib therapy.
Teva Pharmaceutical Industries Ltd. is strengthening its role through generic competition, helping improve affordability and widen patient access in key markets. Its scale in generics makes it an important participant as patent-expiry dynamics continue to reshape the category.
Sandoz Group AG brings strong generic manufacturing and global distribution capabilities, supporting broader availability of dasatinib tablets across multiple regions. The company’s presence reinforces pricing competition and supply chain depth.
Sun Pharmaceutical Industries Limited has expanded its oncology footprint through cost-effective formulations and large-scale manufacturing strength. Its position is especially relevant in price-sensitive markets where access to generics remains a major growth lever.
Hetero Drugs Limited continues to build traction in oncology generics with a focus on emerging markets and high-volume supply capabilities. Its contribution is important in increasing treatment affordability and supporting broader market penetration.
Aurobindo Pharma Limited is an active generic manufacturer in the dasatinib category, with recent regulatory progress in the U.S. supporting its market reach. The company benefits from a diversified pharmaceutical portfolio and global commercialization capabilities.
Dr. Reddy’s Laboratories Limited is leveraging its generic medicine expertise to participate in the expanding dasatinib market. Its focus on accessible therapies aligns with the broader shift toward lower-cost oncology treatment options.
Intas Pharmaceuticals Ltd. has a growing oncology presence and is well positioned to benefit from generic-driven expansion in targeted therapies. The company’s manufacturing and distribution strength supports penetration in international markets.
Cipla Limited is recognized for its strong generics franchise and broad therapeutic reach, which supports its participation in dasatinib commercialization. Its established oncology capabilities enhance its ability to serve both domestic and export markets.
Lupin Limited has recently advanced its dasatinib portfolio in the U.S., signaling stronger participation in regulated markets. Its launch activity underscores how generic entrants are accelerating competition in this space.
Explore our Interactive market dashboard to get a bird's-eye view of the Dasatinib Market. Perform cross-segment analysis, look at market numbers pertaining to specific segments, geographies & timelines, and download these data points in image format that can be used in decks and presentations.
Market Outlook
The outlook for the dasatinib market remains positive as oncology care continues shifting toward targeted and biomarker-driven treatment models. Rising leukemia prevalence, improved diagnostic capabilities, and the spread of generic drug availability are likely to sustain stable demand through 2033.
For PR and media use, the strongest narrative is that dasatinib is evolving from a branded oncology therapy into a broader, more accessible treatment category shaped by generic expansion, regional growth, and persistent clinical need.
I can also turn this into a press release format with headline, subheadline, quote, and boilerplate, or make it more SEO-friendly for LinkedIn and website publishing.
Looking for a report customized to your requirements? Explore our Custom Research Offering
Grand View Research offers
- Focused market intelligence reports on specific geographies or high-growth segments.
- Extended forecast timelines for long-term planning.
- Competitor Benchmarking and Supply Chain Analysis
- Inclusion of regulatory and policy assessments.
- Inclusion of custom data models, KPIs, or applications unique to your business
- Specific high-impact Data Decks and Tables to support effective decision making
And much more…
#DasatinibMarket #OncologyMarket #CMLTreatment #PhPositiveALL #TargetedTherapy #GenericDrugs #PharmaceuticalIndustry #CancerTherapeutics #BristolMyersSquibb #MarketResearch
Comments
Post a Comment